Cartesian Therapeutics (RNAC) Leases (2018 - 2025)
Cartesian Therapeutics (RNAC) has disclosed Leases for 8 consecutive years, with $5.6 million as the latest value for Q4 2025.
- Quarterly Leases rose 1.19% to $5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Dec 2025, up 1.19% year-over-year, with the annual reading at $5.6 million for FY2025, 1.19% up from the prior year.
- Leases for Q4 2025 was $5.6 million at Cartesian Therapeutics, up from $5.0 million in the prior quarter.
- The five-year high for Leases was $13.9 million in Q2 2024, with the low at $3.2 million in Q4 2022.
- Average Leases over 5 years is $9.0 million, with a median of $9.9 million recorded in 2021.
- The sharpest move saw Leases plummeted 67.44% in 2022, then skyrocketed 214.63% in 2023.
- Over 5 years, Leases stood at $9.8 million in 2021, then tumbled by 67.44% to $3.2 million in 2022, then surged by 214.63% to $10.1 million in 2023, then crashed by 45.02% to $5.5 million in 2024, then increased by 1.19% to $5.6 million in 2025.
- According to Business Quant data, Leases over the past three periods came in at $5.6 million, $5.0 million, and $5.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.